Department of Dermatology, Hospital Sultanah Aminah, Clinical School Johor Bahru, Monash University Malaysia, Johor Bahru, Malaysia.
Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Dermatology. 2023;239(3):345-354. doi: 10.1159/000529274. Epub 2023 Feb 16.
Generalized pustular psoriasis (GPP) is a rare, neutrophilic skin disease that can become life-threatening if flares are untreated. There are limited data describing the characteristics and clinical course of GPP disease flares with current treatment options.
The aim of the study was to describe the characteristics and outcomes of GPP flares using historical medical information from patients enrolled in the Effisayil™ 1 trial.
Investigators collected retrospective medical data characterizing patients' GPP flares prior to clinical trial enrollment. Data on overall historical flares were collected, as well as information on patients' typical, most severe, and longest past flares. This included data on systemic symptoms, flare duration, treatment, hospitalization, and time to clearance of skin lesions.
In this cohort (N = 53), patients with GPP experienced a mean of 3.4 flares per year. Flares were painful, associated with systemic symptoms, and often triggered by stress, infections, or treatment withdrawal. Resolution of flares was longer than 3 weeks in 57.1%, 71.0%, and 85.7% of documented (or identified) typical, most severe, and longest flares, respectively. GPP flares led to patient hospitalization in 35.1%, 74.2%, and 64.3% of patients for their typical, most severe, and longest flares, respectively. For the majority of patients, pustules took up to 2 weeks to clear for a typical flare and 3-8 weeks to clear for the most severe and longest flares.
Our findings highlight that current treatment options are slow to control GPP flares and provide context for assessing the efficacy of new therapeutic strategies in patients with a GPP flare.
泛发性脓疱型银屑病(GPP)是一种罕见的中性粒细胞性皮肤病,如果不治疗发作,可能会危及生命。目前关于 GPP 疾病发作的特征和临床病程,以及现有治疗方案的数据有限。
本研究旨在利用 Effisayil™1 试验入组患者的历史医学信息,描述 GPP 发作的特征和结局。
研究人员收集了在临床试验入组前描述患者 GPP 发作特征的回顾性医学数据。收集了关于总体历史发作的数据,以及关于患者典型、最严重和最长过去发作的信息。这包括全身症状、发作持续时间、治疗、住院和皮损清除时间的数据。
在该队列(N=53)中,GPP 患者平均每年发作 3.4 次。发作时疼痛,伴有全身症状,常由压力、感染或治疗中断引发。57.1%、71.0%和 85.7%的典型、最严重和最长发作中,分别有 57.1%、71.0%和 85.7%的患者发作持续时间超过 3 周。53.1%、74.2%和 64.3%的患者因典型、最严重和最长发作而住院。对于大多数患者,脓疱典型发作需 2 周左右清除,最严重和最长发作需 3-8 周清除。
我们的发现强调了现有治疗方案控制 GPP 发作较为缓慢,并为评估新治疗策略在 GPP 发作患者中的疗效提供了背景。